Cholesterol-lowering statins are one of the world’s most commonly used medicines. They were first approved for people with a high risk of cardiovascular disease in 1987. By 2020, global sales were estimated to have approached US$1 trillion (£764 billion).
However, there has been an ongoing debate about whether or not statins are over-prescribed. Does everyone who takes them really benefit from them? To find out, my colleagues and I found 21 relevant clinical trials and analysed the combined data (over 140,000 participants) in what is known as a meta-analysis.
We asked two questions: is it best to lower LDL cholesterol (sometimes known as 'bad' cholesterol) as much as possible to reduce the risk of heart attack, stroke or premature death? And, how do the benefits of statins compare when it comes to reducing the risk of these events?
In answer to the first question, we found a surprisingly weak and inconsistent relationship between the degree of reduction in LDL cholesterol from taking statins and a person’s chance of having a heart attack or stroke, or dying during the trial period. In some trials, reductions in LDL cholesterol were associated with significant reductions in the risk of dying, but in others, reductions in LDL cholesterol did not reduce this risk.
This is an important finding because clinical guidelines have expanded the proportion of people eligible for statins as 'ideal' LDL cholesterol levels were incrementally lowered. For example, one study estimated a 600% increase in eligibility for statins between 1987 and 2016.
Regarding the second question, we looked at two types of risk reduction: relative risk reduction and absolute risk reduction. Imagine your chance of dying from a certain condition prematurely is 0.2%, and there’s a drug that reduces your chance of dying to 0.1%. In relative terms (relative risk reduction), your chance of dying has been halved, or reduced by 50%. But in absolute terms (absolute risk reduction), your chance of dying has only gone down by 0.1%.
Although there is a 50% relative risk reduction, is it a meaningful difference? Would it be worthwhile changing to this drug, particularly if there are side-effects associated with it? Absolute risk reduction presents a clearer picture and makes it easier for people to make informed decisions.
In our study, published in Jama Internal Medicine, we found that the absolute risk reduction from taking statins was modest compared with the relative risk reduction. The relative risk reduction for those taking statins compared with those who did not was 9% for deaths, 29% for heart attacks and 14% for strokes. Yet the absolute risk reduction of dying, having a heart attack or stroke was 0.8%, 1.3% and 0.4% respectively.
A further consideration is that trials report average outcomes across all included participants rather than for an individual. Clearly, people’s individual risk of disease varies depending on lifestyle and other factors. The baseline risk of cardiovascular disease can be estimated using an online calculator, such as QRisk, which takes a range of factors into account, such as weight, smoking, blood pressure, cholesterol and age.
The likelihood of a person developing cardiovascular disease in the next ten years is expressed as a percentage. For example, consider an overweight 65-year-old man who smokes, has high blood pressure and total cholesterol. He may be at high risk of cardiovascular disease, compared with a 45-year-old, non-smoking woman with slightly raised cholesterol and blood pressure and no other risk factors. If a doctor were to assess their risk of dying in the next ten years, the estimated risk for the man might be 38%, for example, whereas the woman’s risk might be only 1.4%.
Now consider the impact of taking statins for both. According to the study, statins would reduce the relative risk of dying by 9%. In absolute terms, the man would reduce his risk from 38% to 34.6%, and the woman from 1.4% to 1.3%.
Patients and their doctors need to consider whether they think these risk reductions are worthwhile in a trade-off between potential benefits and harms, including the inconvenience of taking a daily medicine, possibly for life. This is particularly salient for low-risk people for whom the benefits are marginal. However, people perceive risk differently based on their own experience and preferences, and what might look like a 'good deal' to some may be seen as of little value to others.
Our study highlights that patients and doctors need to be supported to make decisions about treatments using evidence from all available studies and presented in a format that helps them understand potential benefits. Both patients and their doctors need to understand the true impact of medicines in order to make informed decisions. Relying on relative risk, which is numerically more impressive, instead of absolute, may lead both doctors and patients to overestimate the benefits of interventions.
For example, one study found that doctors rated a treatment as more effective and were more likely to prescribe it when the benefits were presented as relative rather than as absolute risk reductions. Another survey found that most respondents would agree to be screened for cancer if presented with relative risk reductions, whereas just over half would if presented with absolute risk reductions.
If you have been prescribed statins, don’t stop taking your medication without first consulting your doctor. Your risk profile might mean that they could benefit you. But if you’d like to reassess taking this drug, ask your doctor to explain your absolute risk reduction and then make a collaborative decision.
This article was originally published in The Conversation on 14 March 2022.
Dr Paula Byrne is a Postdoctoral Research Associate with the RCSI-led and HRB-funded Centre for Primary Care Research.
RCSI is committed to achieving a better and more sustainable future through the UN Sustainable Development Goals.